纳米颗粒对比剂增强CT评估二乙基亚硝胺诱导大鼠肝肿瘤的安全性与可行性
本研究采用18只8周龄雄性F344大鼠,其中6只饮水中含100 ppm二乙基亚硝胺(DEN)8周为腺瘤组,6只含DEN 14周为肝细胞癌(HCC)组,另设对照组和正常肝增强CT组。增强CT使用纳米颗粒对比剂ExiTron nano 12000,结果显示该对比剂可增强肝脏且耐受良好,HCC组CT检出结节数与病理HCC数相关,CT检出HCC大小与病理HCC大小显著相关(r=0.966,p<0.0001)。结论认为该增强CT方法在大鼠肝肿瘤模型中安全可行,可用于测量肿瘤。
要点
- ExiTron nano 12000增强CT可增强大鼠肝脏,15只大鼠耐受检查。
- HCC组CT检出结节数为32.4±8.1个,病理确诊HCC为3.6±2.7个。
- CT检出HCC大小与病理HCC大小显著相关(r=0.966,p<0.0001)。
核心结论
- 使用ExiTron nano 12000的增强CT在大鼠肝肿瘤模型中安全可行,可用于测量肿瘤。
研究设计与样本
- 研究采用18只8周龄雄性F344大鼠,分为对照组、正常肝增强CT组、腺瘤组(饮水中含100 ppm DEN 8周)和HCC组(含DEN 14周),每组6只。
- 增强CT使用纳米颗粒对比剂ExiTron nano 12000,以组织病理学(HE染色)为参考标准评估肝结节。
关键影像表现/征象
- ExiTron nano 12000增强CT可增强肝脏,15只大鼠完成增强CT且耐受良好。
- 腺瘤组CT检出结节数为14.8±5.1个,HCC组为32.4±8.1个。
- HCC组病理确诊HCC为3.6±2.7个,CT检出HCC大小与病理HCC大小显著相关(r=0.966,p<0.0001)。
诊断标准与关键数值
- HCC组CT检出结节与HE染色病理结节进行诊断一致性评估,CT检出HCC大小与病理HCC大小相关系数r=0.966(p<0.0001)。
临床应用与阅片要点
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Safety and feasibility of contrast-enhanced computed tomography (CECT) with a nanoparticulate contrast agent, ExiTron nano 12000, was evaluated in a rat liver tumor model.
MATERIALS AND METHODS: This study employed eighteen 8-week-old male F344 rats. Six rats given tap water for 8 weeks further divided into two: Control group and Normal Liver with CECT group. Six rats each were given tap water containing diethylnitrosamine (DEN) at 100 ppm for 8 or 14 weeks; Adenoma group and Hepatocellular carcinoma (HCC) group, respectively. Biochemical marker values and adverse events were evaluated after CT imaging. ExiTron nano 12000 was evaluated for the hepatic contrast enhancement, and the detection and measurement of liver nodules by CECT after 8- and 14-weeks administration of DEN. Post-mortem liver specimens were evaluated by hematoxylin-eosin (HE) staining, and the number and size of liver nodules were measured. The HCC group was evaluated for diagnostic concordance between HE-stained and CECT-detected nodules.
RESULTS: The contrast agent enhanced liver and was tolerated after CECT in 15 rats. Biochemical parameter values did not differ significantly between the Control and Normal Liver groups. The numbers of CECT-detected nodules in the Adenoma and HCC groups were 14.8 ± 5.1, and 32.4 ± 8.1, respectively. The HCC group had 3.6 ± 2.7 of pathological HCCs, which were identified by CECT. The size of CECT-detected HCCs correlated significantly with that of pathological HCCs (r = 0.966, p < 0.0001).
CONCLUSION: CECT with ExiTron nano 12000 is a safe and feasible method to measure tumors in a rat liver tumor model.
引用
- Nota, Kageyama, Yamamoto, et al. Safety and Feasibility of Contrast-Enhanced Computed Tomography with a Nanoparticle Contrast Agent for Evaluation of Diethylnitrosamine-Induced Liver Tumors in a Rat Model. Acad Radiol. 2022. PMID: 35680546. doi:10.1016/j.acra.2022.03.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。